ArticleFrontiers in medicine2026
Impact of Rh five-antigen-matched transfusion on alloimmunization and clinical outcomes in patients requiring repeated red blood cell transfusions: a prospective randomized controlled study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Red blood cell (RBC) alloimmunization remains a significant challenge in patients requiring repeated transfusions, complicating transfusion procedures and increasing healthcare resource utilization. While extended Rh antigen matching has been proposed to mitigate alloimmunization, prospective data on its impact on transfusion-related outcomes and clinical management remain limited. Methods: In this prospective, randomized controlled study, patients requiring multiple RBC transfusions were randomly assigned to receive either conventional antigen matching or Rh five-antigen (D, C, c, E, e)-matched transfusions. The primary endpoint was the incidence of RBC alloantibody formation. Secondary endpoints included transfusion-related adverse reactions, as well as transfusion management outcomes such as RBC utilization, transfusion intervals, and length of hospital stay. Multivariable analyses were performed to adjust for potential confounders. Results: Patients in the Rh five-antigen-matched group demonstrated a significantly lower incidence of alloantibody formation and fewer transfusion-related adverse reactions compared to the conventional matching group. Additionally, Rh five-antigen matching was associated with reduced RBC utilization, longer transfusion intervals, and shorter hospital stays. After adjusting for relevant clinical variables, Rh five-antigen-matched transfusion remained independently associated with lower RBC utilization. Conclusion: In patients requiring repeated RBC transfusions, Rh five-antigen-matched transfusion was associated with a reduced risk of alloantibody formation and more favorable transfusion management outcomes. This strategy represents a viable transfusion management approach for patients at high immunological risk, and its long-term clinical value and cost-effectiveness should be further explored in multicenter studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.